跳至主要内容
临床试验/NCT00600769
NCT00600769已完成4 期

Open Study of Clarithromycin for the Treatment of Infections Caused by Nontuberculous Mycobacteria (NTM)

The University of Texas Health Science Center at Tyler1 个研究点 分布在 1 个国家目标入组 210 人开始时间: 1991年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
210
试验地点
1
主要终点
Clinical and microbiological outcomes, such as clinical symptoms and laboratory cultures

研究概览

简要总结

Use of oral clarithromycin for treatment of chronic lung disease due to Mycobacterium avium-intracellulare and other non-tuberculous Mycobacteria

详细描述

Oral clarithromycin for treatment of MAC and other nontuberculous mycobacteria in adults with clinical history

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Meet American Thoracic Society criteria for nontuberculous lung disease: two or more AFB smear positive, culture positive sputums or bronchoscopic samples and/or two or more AFB smear negative respiratory samples with moderate to heavy growth (2+-4+); abnormal CXR consistent with M. avium lung disease; absence of other potential lung pathogens (except for the coexistence of M. abscessus)
  • Age 18 years and older

排除标准

  • History of macrolide allergy
  • Must not receive the antihistamines terfenadine (Seldane) or astemizole (Hismanal) while on clarithromycin
  • Children less than 18 years of age
  • If a menstruating female, not pregnant and on adequate birth control

研究组 & 干预措施

treatment of MAC and other NTM

Other

Clarithromycin drug given twice daily.

干预措施: Clarithromycin (Drug)

结局指标

主要结局

Clinical and microbiological outcomes, such as clinical symptoms and laboratory cultures

时间窗: 6 months

neg culture x3( sputum conversion)

次要结局

  • Microbiological cultures(1yr)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Richard J. Wallace, Jr., M.D.

Chairman Department of Microbiology

The University of Texas Health Science Center at Tyler

研究点 (1)

Loading locations...

相似试验